logo-loader
viewCytoDyn

CytoDyn's flagship drug leronlimab to be tested to prevent fatty liver diease in mice

The goal of the exploratory pre-clinical studies are to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH

lab workers
NASH is difficult to diagnose and there are currently no therapies approved by the FDA

CytoDyn Inc (OTCMKTS:CYDY) announced Monday that The Cleveland Clinic will test its flagship drug leronlimab (PRO 14O) to determined if it can prevent Non-Alcoholic Steatohepatitis (NASH) in mice.

The goal of the exploratory pre-clinical studies by Dr. Daniel Linder is to establish leronlimab’s ability to prevent the progression of Non-Alcoholic Fatty Liver Disease (NAFLD) into NASH, the Vancouver, Washington-based company said in a statement.

CytoDyn noted that Pfizer’s (NYSE:PFE) HIV drug maraviroc has been a subject of several positive studies in this field. “Thus, CytoDyn intends to pursue this opportunity,” the company said.

READ: CytoDyn secures fast track FDA designation for leronlimab in treating metastatic triple negative breast cancer

“A successful proof-of-concept study of leronlimab in NASH will allow the company to immediately file with the FDA an (investigational new drug program) and protocol for a Phase 2 trial,” said CEO Nader Pourhassan.

NAFLD is an inflammatory disease caused by the build-up of fat in the liver of people who drink little or no alcohol. In severe cases, NAFLD progresses into NASH. It is estimated that 30% to 40% of adults in the US have NAFLD, while 3% to 12% of adults in the US have NASH, the company said.

If left untreated, NASH can progress to more serious disease stages, such as advanced fibrosis, cirrhosis, liver failure or liver cancer. CytoDyn said the disease is expected to become the leading cause of liver transplants by 2020.

Despite the growing awareness of NASH, it remains difficult to diagnose and there are currently no therapies approved by the US Food and Drug Administration.

Meanwhile, the CCR5 pathway has been shown in multiple clinical trials and in unrelated third-party research to be a potential key target in NASH, and leronlimab is a highly selective CCR5 inhibitor, CytoDyn said.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: CytoDyn

Price: 0.3002 USD

OTCMKTS:CYDY
Market: OTCMKTS
Market Cap: $116.55 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn CEO addresses share price activity, and upcoming...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan talks to Proactive about recent pressure the company has seen on its share price, and how the company plans to address it. Pourhassan also reveals the company is 'very close' to announcing major details on out-licensing leronlimab in the US,...

2 weeks, 1 day ago

2 min read